The Treatment of Lichen Sclerosus with Topical Roflumilast 0.3% Case Study
Main Article Content
Keywords
Lichen Sclerosus, Topical Roflumilast 0.3%, Lichen Sclerosus treated with topical roflumilast 0.3% once daily
Abstract
Lichen Sclerosus is a chronic inflammatory skin disease predominantly affecting post-menopausal women. Currently, the first line treatment approach for lichen sclerosus is ultra potent topical corticosteroids for 12 weeks. A treatment challenge to this approach is the risk of steroid atrophy due to the use of potent topical steroids on the genital skin. We describe reduction of erythema and symptomatic improvement following treatment with topical roflumilast 0.3% once daily in a patient with lichen sclerosus who refused topical corticosteroids.
References
1. Kirtschig G. Lichen Sclerosus-Presentation, Diagnosis and Management. Dtsch Arztebl Int. 2016 May 13;113(19):337-43. doi: 10.3238/arztebl.2016.0337. PMID: 27232363; PMCID: PMC4904529.
2. Altman, DA. Palmoplantar pustulosis successfully treated with topical roflumilast 0.3%. Journal of Dermatology for Physician Assistants 2024.18(3):p 34-35. DOI: 10.1097/jdpa.0000000000000027
3. ZORYVE (roflumilast) topical cream [prescribing information online]. Westlake Village, CA: Arcutis Biotherapeutics. July 2022. Available at: USPI-roflumilast-cream-FDAapproved-V1-29Jul2022.pdf (arcutis.com). Accessed
4. Stacey SK and Mceleney M. Topical Corticosteroids: Choice and Application; American Family Physician. 2021;103(6):337-343.
2. Altman, DA. Palmoplantar pustulosis successfully treated with topical roflumilast 0.3%. Journal of Dermatology for Physician Assistants 2024.18(3):p 34-35. DOI: 10.1097/jdpa.0000000000000027
3. ZORYVE (roflumilast) topical cream [prescribing information online]. Westlake Village, CA: Arcutis Biotherapeutics. July 2022. Available at: USPI-roflumilast-cream-FDAapproved-V1-29Jul2022.pdf (arcutis.com). Accessed
4. Stacey SK and Mceleney M. Topical Corticosteroids: Choice and Application; American Family Physician. 2021;103(6):337-343.